Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.

@article{Slevin2007UnilateralIG,
  title={Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.},
  author={John T. Slevin and Don Marshall Gash and Charles D. Smith and Greg A. Gerhardt and Richard Kryscio and Himachandra Chebrolu and Ashley Walton and Ren{\'e}e M. Wagner and Anne B. Young},
  journal={Journal of neurosurgery},
  year={2007},
  volume={106 4},
  pages={614-20}
}
OBJECT Glial cell line-derived neurotrophic factor (GDNF) infused unilaterally into the putamen for 6 months has been previously shown to improve significantly motor functions and quality of life measures in 10 patients with Parkinson disease (PD) in a Phase I trial. In the present study the authors report the safety and efficacy of continuous treatment for a minimum of 1 year. After the trial was halted by the drug sponsor, the patients were monitored for an additional 1 year during which the… CONTINUE READING